Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study

This prospective multicenter study evaluated the prognostic value of circulating tumor cells (CTCs) in relapsing nonoperable or metastatic head and neck squamous cell carcinoma (rHNSCC) treated by chemotherapy and cetuximab. In 65 patients suitable for analyses, peripheral blood was taken at day 0 (...

Full description

Saved in:
Bibliographic Details
Published in:Clinical chemistry (Baltimore, Md.) Md.), 2019-10, Vol.65 (10), p.1267-1275
Main Authors: Garrel, Renaud, Mazel, Martine, Perriard, Françoise, Vinches, Marie, Cayrefourcq, Laure, Guigay, Joël, Digue, Laurence, Aubry, Karine, Alfonsi, Marc, Delord, Jean-Pierre, Lallemant, Benjamin, Even, Caroline, Daurès, Jean-Pierre, Landais, Paul, Cupissol, Didier, Alix-Panabières, Catherine
Format: Article
Language:English
Subjects:
Biopsy
Breast cancer
Cancer
Cancer therapies
Chemotherapy
Evaluation
Flow cytometry
Head & neck cancer
Life Sciences
Medical prognosis
Metastases
Metastasis
Monoclonal antibodies
Peripheral blood
Prostate cancer
Rank tests
Squamous cell carcinoma
Studies
Systematic review
Targeted cancer therapy
Tumor cells
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This prospective multicenter study evaluated the prognostic value of circulating tumor cells (CTCs) in relapsing nonoperable or metastatic head and neck squamous cell carcinoma (rHNSCC) treated by chemotherapy and cetuximab. In 65 patients suitable for analyses, peripheral blood was taken at day 0 (D ) D , and D of treatment for CTC detection by CellSearch , EPISPOT, and flow cytometry (FCM). Progression-free survival (PFS) was assessed with the Kaplan-Meier method and compared with the log-rank test ( < 0.05). At D , CTCs were detected with EPISPOT, CellSearch, and FCM in 69% (45/65), 21% (12/58), and 11% (7/61) of patients, respectively. In the patients tested with all 3 methods, EPISPOT identified 92% (36/39), 92% (35/38), and 90% (25/28) of all positive samples at D , D , and D , respectively. Median PFS time was significantly lower in ( ) patients with increasing or stable CTC counts (36/54) from D to D with EPISPOT (3.9 vs 6.2 months; 95% CI, 5.0-6.9; = 0.0103) and ( ) patients with ≥1 CTC detected with EPISPOT or CellSearch (37/51) ( = 0.0311), EPISPOT or FCM (38/54) ( = 0.0480), and CellSearch or FCM (11/51) ( = 0.0005) at D . CTCs can be detected before and during chemotherapy in patients with rHNSCC. D -D CTC kinetics evaluated with EPISPOT are associated with the response to treatment. This study indicates that CTCs can be used as a real-time liquid biopsy to monitor the early response to chemotherapy in rHNSCC. NCT02119559.
ISSN:0009-9147
1530-8561
DOI:10.1373/clinchem.2019.305904